Immunovant, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor.
March 12, 2024
· 4 min read
